Alzheimer Disease Clinical Trial
Official title:
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
Verified date | March 2024 |
Source | Axsome Therapeutics, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the long-term safety and efficacy of AXS-05 in subjects with Alzheimer's disease (AD) agitation.
Status | Enrolling by invitation |
Enrollment | 300 |
Est. completion date | December 2024 |
Est. primary completion date | December 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years to 90 Years |
Eligibility | Inclusion Criteria: - Participation in Study AXS-05-AD-302 or Study AXS-05-AD-304. - Caregiver is willing to communicate with site personnel, comply with all required study procedures, and oversee administration and compliance with the subject's study treatment. Exclusion Criteria: - Caregiver is unwilling or unable, in the opinion of the investigator, to comply with study instructions. - Subject is hospitalized in a mental health facility (e.g., psychiatric hospital or ward), living in a nursing home, or living alone. - Any concurrent medical condition that might interfere with the conduct of the study, confound the interpretation of study results, or endanger the subject's well-being. - Initiation of a new medication since enrolling in AXS-05-AD-302 or AXS-05-AD-304 which may pose a safety risk when taken concurrently with AXS-05. |
Country | Name | City | State |
---|---|---|---|
Canada | Clinical Research Site | Kelowna | British Columbia |
United States | Clinical Research Site | Arlington | Virginia |
United States | Clinical Research Site | Austin | Texas |
United States | Clinical Research Site | Brandon | Florida |
United States | Clinical Research Site | Brooklyn | New York |
United States | Clinical Research Site | Chesterfield | Missouri |
United States | Clinical Research Site | Columbus | Georgia |
United States | Clinical Research Site | Coral Springs | Florida |
United States | Clinical Research Site | Cypress | Texas |
United States | Clinical Research Site | Flint | Michigan |
United States | Clinical Research Site | Greenacres City | Florida |
United States | Clinical Research Site | Hialeah | Florida |
United States | Clinical Research Site | Hickory | North Carolina |
United States | Clinical Research Site | Hollywood | Florida |
United States | Clinical Research Site | Kissimmee | Florida |
United States | Clinical Research Site | Lafayette | California |
United States | Clinical Research Site | Lake City | Florida |
United States | Clinical Research Site | Long Beach | California |
United States | Clinical Research Site | McKinney | Texas |
United States | Clinical Research Site | Miami | Florida |
United States | Clinical Research Site | Miami | Florida |
United States | Clinical Research Site | Miami | Florida |
United States | Clinical Research Site | Miami | Florida |
United States | Clinical Research Site | Miami | Florida |
United States | Clinical Research Site | Miami | Florida |
United States | Clinical Research Site | Miami | Florida |
United States | Clinical Research Site | Miami Gardens | Florida |
United States | Clinical Research Site | Miami Lakes | Florida |
United States | Clinical Research Site | New Windsor | New York |
United States | Clinical Research Site | Orlando | Florida |
United States | Clinical Research Site | Pembroke Pines | Florida |
United States | Clinical Research Site | Peoria | Arizona |
United States | Clinical Research Site | Rochester Hills | Michigan |
United States | Clinical Research Site | Santa Ana | California |
United States | Clinical Research Site | Staten Island | New York |
United States | Clinical Research Site | Sugar Land | Texas |
United States | Clinical Research Site | Temecula | California |
United States | Clinical Research Site | Toms River | New Jersey |
United States | Clinical Research Site | Trinity | Florida |
United States | Clinical Research Site | Wichita | Kansas |
Lead Sponsor | Collaborator |
---|---|
Axsome Therapeutics, Inc. |
United States, Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Cohen-Mansfield Agitation Inventory (CMAI) | Change from Baseline to last dose in the CMAI | up to 76 weeks | |
Primary | Long-term Safety | Incidence of treatment-emergent adverse events following dosing with AXS-05 | up to 76 weeks | |
Primary | Time to relapse of agitation symptoms | up to 24 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Completed |
NCT04079803 -
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT04520698 -
Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease
|
N/A | |
Active, not recruiting |
NCT04606420 -
Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05820919 -
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
|
N/A | |
Terminated |
NCT03672474 -
REGEnLIFE RGn530 - Feasibility Pilot
|
N/A | |
Completed |
NCT03430648 -
Is Tau Protein Linked to Mobility Function?
|
||
Recruiting |
NCT04949750 -
Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease
|
N/A | |
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT04522739 -
Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease
|
Phase 4 | |
Recruiting |
NCT05557409 -
A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation
|
Phase 3 | |
Completed |
NCT06194552 -
A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07
|
Phase 1 | |
Completed |
NCT03239561 -
Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants
|
Early Phase 1 | |
Completed |
NCT03184467 -
Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients
|
Phase 2 | |
Active, not recruiting |
NCT03676881 -
Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
|
||
Terminated |
NCT03487380 -
Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT05328115 -
A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease
|
Phase 1 | |
Completed |
NCT05562583 -
SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support
|
N/A |